Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is an early/clinical stage drug development company with a focus on developing cannabinoid-based formulations for the treatment of Alzheimer’s disease. The company has multiple promising drug candidates and has reported positive interim results from its ongoing trials for the treatment of agitation in Alzheimer’s patients. Its recent change in fiscal year end to align with other major pharmaceutical companies and potential upcoming milestones make it an attractive investment, but risks include liquidity, regulatory approval, and competition in the biotech industry.

Bears say

IGC Pharma is an early/clinical stage drug development company focused on developing novel therapies for Alzheimer's disease. While it has reported positive results in preclinical studies and recently achieved over 70% patient enrollment in its Phase 2 CALMA trial, its current revenue is minimal and its net loss is larger than expected. Furthermore, the company's goal of completing its CALMA trial and releasing its AI beta program in mid-2026 may be ambitious, leading to potential delays and increased risks. Overall, the stock's current valuation may be attractive, but the high risks and uncertainties surrounding the company's pipeline and financials warrant a negative outlook.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.